Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.
In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.
In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.